Death Caps and Dubious Cures: Current and Emerging Pharmacotherapies for Amanita Toxicity

Dangerous death cap or peaceful puffball? When foraging goes wrong, clinicians are often left navigating the hepatotoxic consequences of these culinary misadventures. α-Amanitin poisoning is a rare but potentially fatal poisoning with few well-studied therapeutic options. Supportive care with aggressive fluid and electrolyte resuscitation is typically warranted in the setting of significant gastrointestinal losses from vomiting and diarrhea, and activated charcoal is recommended to adsorb amatoxin and interrupt its enterohepatic recirculation. Beyond supportive care, however, targeted therapies are limited and lack robust clinical evidence. Here, we present a rapid-fire review of proposed pharmacotherapies for Amanita toxicity, including their mechanisms of action and the existing data surrounding their efficacy. N-acetylcysteine (NAC) is generally recommended in Amanita toxicity due to its ability to reduce oxidative stress and provide hepatoprotective effects, as well as its favorable safety profile. One systematic review demonstrated safe and potentially beneficial use of NAC across 13 studies, utilizing doses equivalent to those used for acetaminophen toxicity. Several therapies have been proposed to competitively inhibit organic anion transporting polypeptide 1B3 (OATP1B3), thereby reducing hepatocyte uptake of amatoxin and limiting enterohepatic recirculation. High-dose penicillin G has demonstrated some efficacy in animal models; however, its use is generally limited due to minimal clinical evidence and the potential risk of seizures at high doses. Cyclosporine has also been shown to inhibit OATP1B3 and may reduce hepatocyte apoptosis, though clinical data supporting its use remain sparse. Silibinin, an extract derived from milk thistle, similarly inhibits OATP1B3 and is available over the counter as oral silymarin. An intravenous formulation is available in Europe and may be considered preferred antidotal therapy where available. Other proposed therapies include polymyxin B, which has demonstrated competitive inhibition of amatoxin binding to RNA polymerase II in murine models and has been suggested as a potential antidotal therapy at doses of at least 0.75 mg/kg, though human data are limited. Octreotide has been proposed as adjunctive therapy due to its ability to reduce gallbladder contractility, potentially decreasing enterohepatic recirculation of amatoxin. Another emerging therapy includes indocyanine green, which has been shown to inhibit STT3B, a catalytic enzyme required for amatoxin-mediated toxicity. Amatoxin poisoning remains a rare and diagnostically challenging toxicity with limited evidence-based treatment options. Pharmacists play a critical role in understanding the mechanisms, potential benefits, and limitations of proposed therapies and in supporting multidisciplinary management and clinical decision-making.